BMY Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 39.21%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Bristol Myers Squibb Co. has a consensus price target of $58.04, signalling upside risk potential of 5.44%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $138.49 which suggests that it could fall by -2.76%. Given that Bristol Myers Squibb Co. has higher upside potential than Gilead Sciences, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Gilead Sciences, Inc..

Bristol Myers Squibb Co. has a beta of 0.288, which suggesting that the stock is 71.215% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.63 per share corresponding to a yield of 4.52%. Gilead Sciences, Inc. offers a yield of 2.23% to investors and pays a quarterly dividend of $0.79 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. Bristol Myers Squibb Co.'s net income of $2.2B is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.59x while Gilead Sciences, Inc.'s PE ratio is 21.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.34x versus 6.14x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics, Inc. has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of -243.13%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.

Bristol Myers Squibb Co. has a consensus price target of $58.04, signalling upside risk potential of 5.44%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $63.59 which suggests that it could grow by 363.81%. Given that Janux Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Janux Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..

Bristol Myers Squibb Co. has a beta of 0.288, which suggesting that the stock is 71.215% less volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.63 per share corresponding to a yield of 4.52%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are larger than Janux Therapeutics, Inc. quarterly revenues of $10M. Bristol Myers Squibb Co.'s net income of $2.2B is higher than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.59x while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.34x versus 83.13x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 20.83%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Johnson & Johnson's return on equity of 33.27%.

Bristol Myers Squibb Co. has a consensus price target of $58.04, signalling upside risk potential of 5.44%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could grow by 1.49%. Given that Bristol Myers Squibb Co. has higher upside potential than Johnson & Johnson, analysts believe Bristol Myers Squibb Co. is more attractive than Johnson & Johnson.

Bristol Myers Squibb Co. has a beta of 0.288, which suggesting that the stock is 71.215% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.63 per share corresponding to a yield of 4.52%. Johnson & Johnson offers a yield of 2.26% to investors and pays a quarterly dividend of $1.30 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Bristol Myers Squibb Co.'s net income of $2.2B is lower than Johnson & Johnson's net income of $5.1B. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.59x while Johnson & Johnson's PE ratio is 20.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.34x versus 5.86x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 21.74%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Bristol Myers Squibb Co. has a consensus price target of $58.04, signalling upside risk potential of 5.44%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $846.85 which suggests that it could grow by 12.75%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Bristol Myers Squibb Co..

Bristol Myers Squibb Co. has a beta of 0.288, which suggesting that the stock is 71.215% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.63 per share corresponding to a yield of 4.52%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Bristol Myers Squibb Co.'s net income of $2.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.59x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.34x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.